Shares of METIS TECHBIO-P (07666) climbed more than 15% in the morning trading session, taking the lead among AI drug development concept stocks. As of the time of writing, the stock was up 12.81%, trading at HK$15.59, with a turnover of HK$110 million.

On the news front, the Shanghai Stock Exchange issued a notice after the market close on September 4th, announcing that METIS TECHBIO-P has been officially added to the list of securities eligible for the Stock Connect program. This adjustment will take effect on Monday, September 7th. This move means that mainland investors can now directly buy and sell METIS TECHBIO-P shares through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect channels, officially unlocking southbound capital flows. The board of directors believes that this inclusion will help broaden the shareholder base, attract long-term institutional investors, and enhance the liquidity of share trading.

Notably, during the first half of the year, the commercialization results of METIS TECHBIO-P's NanoForge platform entered a period of concentrated release. During the period, revenue exceeded RMB 154 million, surpassing 47% of the total revenue for the previous full year. The adjusted net loss narrowed significantly by 56.4% to RMB 51 million, while research and development expenses increased by 48.1% year-on-year to RMB 172 million.

During the reporting period, the company's platform capabilities expanded from designing drug delivery systems to the systematic design of proteins, nucleic acids, delivery systems, and cellular states. The AI-driven nano-delivery platform NanoForge is accelerating its commercialization process within the AI for Science (AI4S) field.